HBM Healthcare swings to CHF 238 million Q1 FY27 profit; NAV per share rises 13%

Reuters2026/07/24 04:40

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

HBM Healthcare Investments posted a profit of CHF 238 million in Q1 FY2026/27; net assets topped CHF 2 billion at June 30, 2026.
NAV per share rose 13% in the quarter; the share price climbed 8.9%, leaving a roughly 23% discount to NAV.
Public holdings delivered CHF 183 million of the quarterly result, with gains described as broad-based across multiple positions.
Private investments added CHF 105 million, driven by Curevo’s announced sale to Eli Lilly, IPOs at Parabilis and Odyssey, and Dren Bio’s financing uplift.
Two private deals were added: Lycia Therapeutics (USD 9 million) and CellCentric (USD 12.5 million); the firm expects a supportive biotech backdrop.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2371034_en) on July 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

HBM Healthcare swings to CHF 238 million Q1 FY27 profit; NAV per share rises 13%

You may also like

Crypto prices